Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.

Autor:	Zhang K; Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China., Teoh J; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China., Zhu G; Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China., Ng CF; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China., Suberville M; Department of Urology, Pôle Saint Germain Centre Hospitalier de BRIVE, Brive la Gaillarde, France., Laguna P; Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Türkiye., de la Rosette J; Department of Urology, Medipol Mega Hospital, Istanbul Medipol University, Istanbul, Türkiye. j.j.delarosette@gmail.com.
Jazyk:	angličtina
Zdroj:	The world journal of men's health [World J Mens Health] 2024 Jul 03. Date of Electronic Publication: 2024 Jul 03.
DOI:	10.5534/wjmh.240012
Abstrakt:	Purpose: Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique. Materials and Methods: A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality. Results: The in-field clinically significant prostate cancer rate was reported between 0%-15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%-96.8%. The post-operative pad-free rate ranged between 96.7%-100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare. Conclusions: These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients' urinary and erectile function. Competing Interests: The authors have nothing to disclose. (Copyright © 2024 Korean Society for Sexual Medicine and Andrology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu